297 related articles for article (PubMed ID: 33645382)
1. Cholangiocarcinoma: shedding light on the most promising drugs in clinical development.
Rahnemai-Azar AA; Pawlik TM
Expert Opin Investig Drugs; 2021 Apr; 30(4):419-427. PubMed ID: 33645382
[No Abstract] [Full Text] [Related]
2. Emerging pathways for precision medicine in management of cholangiocarcinoma.
Rahnemai-Azar AA; Abbasi A; Acher AW; Weber SM; Pawlik TM
Surg Oncol; 2020 Dec; 35():47-55. PubMed ID: 32827952
[TBL] [Abstract][Full Text] [Related]
3. Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials.
Bourien H; Lamarca A; McNamara MG; Hubner RA; Valle JW; Edeline J
Expert Opin Investig Drugs; 2021 Sep; 30(9):975-983. PubMed ID: 34420429
[No Abstract] [Full Text] [Related]
4. Novel targeted treatment options for advanced cholangiocarcinoma.
Mahipal A; Kommalapati A; Tella SH; Lim A; Kim R
Expert Opin Investig Drugs; 2018 Sep; 27(9):709-720. PubMed ID: 30124336
[TBL] [Abstract][Full Text] [Related]
5. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
Aitcheson G; Mahipal A; John BV
Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096
[No Abstract] [Full Text] [Related]
6. Cholangiocarcinoma: bridging the translational gap from preclinical to clinical development and implications for future therapy.
Baiocchi L; Sato K; Ekser B; Kennedy L; Francis H; Ceci L; Lenci I; Alvaro D; Franchitto A; Onori P; Gaudio E; Wu C; Chakraborty S; Glaser S; Alpini G
Expert Opin Investig Drugs; 2021 Apr; 30(4):365-375. PubMed ID: 33226854
[No Abstract] [Full Text] [Related]
7. Cholangiocarcinoma: novel therapeutic targets.
Sato K; Glaser S; Alvaro D; Meng F; Francis H; Alpini G
Expert Opin Ther Targets; 2020 Apr; 24(4):345-357. PubMed ID: 32077341
[No Abstract] [Full Text] [Related]
8. Molecular pathways and targeted therapy in cholangiocarcinoma.
Dabney RS; Khalife M; Shahid K; Phan AT
Clin Adv Hematol Oncol; 2019 Nov; 17(11):630-637. PubMed ID: 31851165
[TBL] [Abstract][Full Text] [Related]
9. Cholangiocarcinoma: investigations into pathway-targeted therapies.
Ntanasis-Stathopoulos I; Tsilimigras DI; Gavriatopoulou M; Schizas D; Pawlik TM
Expert Rev Anticancer Ther; 2020 Sep; 20(9):765-773. PubMed ID: 32757962
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic challenges at the preclinical level for targeted drug development for
Loilome W; Dokduang H; Suksawat M; Padthaisong S
Expert Opin Investig Drugs; 2021 Sep; 30(9):985-1006. PubMed ID: 34292795
[TBL] [Abstract][Full Text] [Related]
11. Developing models of cholangiocarcinoma to close the translational gap in cancer research.
Waddell SH; Boulter L
Expert Opin Investig Drugs; 2021 Apr; 30(4):439-450. PubMed ID: 33513027
[No Abstract] [Full Text] [Related]
12. Molecular genetics and targeted therapeutics in biliary tract carcinoma.
Marks EI; Yee NS
World J Gastroenterol; 2016 Jan; 22(4):1335-47. PubMed ID: 26819503
[TBL] [Abstract][Full Text] [Related]
13. Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives.
Rizzo A; Ricci AD; Brandi G
Expert Opin Investig Drugs; 2021 Apr; 30(4):317-324. PubMed ID: 33054456
[TBL] [Abstract][Full Text] [Related]
14. Intrahepatic cholangiocarcinoma: current management and emerging therapies.
Rahnemai-Azar AA; Weisbrod AB; Dillhoff M; Schmidt C; Pawlik TM
Expert Rev Gastroenterol Hepatol; 2017 May; 11(5):439-449. PubMed ID: 28317403
[TBL] [Abstract][Full Text] [Related]
15. The impact of molecular profiling on cholangiocarcinoma clinical trials and experimental drugs.
Sipra QUAR; Shroff R
Expert Opin Investig Drugs; 2021 Apr; 30(4):281-284. PubMed ID: 33228417
[No Abstract] [Full Text] [Related]
16. Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications.
Kankeu Fonkoua LA; Serrano Uson Junior PL; Mody K; Mahipal A; Borad MJ; Roberts LR
Expert Opin Ther Targets; 2022 Jan; 26(1):79-92. PubMed ID: 35034558
[TBL] [Abstract][Full Text] [Related]
17. Regorafenib, an investigational agent for the treatment of cholangiocarcinoma.
Sahin IH; Tan E; Kim R
Expert Opin Investig Drugs; 2021 Apr; 30(4):333-341. PubMed ID: 33378249
[TBL] [Abstract][Full Text] [Related]
18. Cholangiocarcinoma: molecular pathways and therapeutic opportunities.
I Ilyas S; Borad MJ; Patel T; Gores GJ
Semin Liver Dis; 2014 Nov; 34(4):456-64. PubMed ID: 25369307
[TBL] [Abstract][Full Text] [Related]
19. Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?
Braconi C; Roessler S; Kruk B; Lammert F; Krawczyk M; Andersen JB
Liver Int; 2019 May; 39 Suppl 1():32-42. PubMed ID: 30829432
[TBL] [Abstract][Full Text] [Related]
20. Updates in the use of targeted therapies for the treatment of cholangiocarcinoma.
Lodl E; Ramnaraign B; Sahin I; Wheeler S
J Oncol Pharm Pract; 2023 Jul; 29(5):1206-1217. PubMed ID: 37097888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
